Bristol Myers: new data on schizophrenia

(CercleFinance.com) - Bristol Myers Squibb presents new interim pooled long-term safety and metabolic outcome data from the EMERGENT program evaluating KarXT in schizophrenia at the 2024 Annual Meeting of the International Society for Schizophrenia Research.


KarXT demonstrated a favorable long-term metabolic profile, with most patients experiencing stable or improved metabolic parameters over 52 weeks of treatment.

The majority of patients (65%) experienced weight loss during the trial, with a mean weight reduction of 2.6 kg observed at one year.

The data show no significant prolactin-related changes or clinically meaningful changes in movement disorder scale scores over 52 weeks

' These long-term safety and metabolic results from the EMERGENT program are extremely encouraging, as they allow us to better understand the tolerability profile of KarXT in people with schizophrenia ', said Roland Chen, MD, Senior Vice President and Head of Immunology, Cardiovascular and Neuroscience Development at Bristol Myers Squibb.

BMS adds that it is promising that during one year of treatment, KarXT was not associated with burdensome side effects, particularly weight gain and metabolic dysfunction, as well as extrapyramidal symptoms, underscoring its potential to provide a meaningful and differentiated option for people with schizophrenia.


Copyright (c) 2024 CercleFinance.com. All rights reserved.